Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
暂无分享,去创建一个
K R Abrams | K J O'Byrne | K. O'Byrne | K. Abrams | D. Waller | J. Edwards | T. Spyt | J G Edwards | J N Leverment | T J Spyt | D A Waller | J. Leverment
[1] V. Rusch,et al. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.
[2] T. Hickish,et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] B. Weyn,et al. Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.
[4] K. R. Patel,et al. Clinical Features and Epidemiology of Malignant Pleural Mesothelioma in West Glasgow 1987–1992 , 1997, Scottish medical journal.
[5] S. Franceschi,et al. Prognostic factors of malignant mesothelioma of the pleura , 1993, Cancer.
[6] D. Yates,et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. , 1997, Thorax.
[7] G. Dabouis,et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. , 1988, Chest.
[8] L. Tammilehto. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients , 1992 .
[9] E. Borden,et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Weyler,et al. EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA , 1997, The Journal of pathology.
[11] W. Richards,et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.
[12] D.,et al. Regression Models and Life-Tables , 2022 .
[13] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. A. van der Merwe,et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Prognostic factors of malignant mesothelioma of the pleura. , 1993, Cancer.
[16] R. K. Bright,et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.
[17] V. Rusch,et al. The importance of surgical staging in the treatment of malignant pleural mesothelioma. , 1996, The Journal of thoracic and cardiovascular surgery.
[18] D. Sugarbaker,et al. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma. , 1997, Seminars in thoracic and cardiovascular surgery.
[19] S. Steinberg,et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. , 1998, The Journal of thoracic and cardiovascular surgery.
[20] L. Norton,et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. , 1982, Annals of internal medicine.
[21] F Levi,et al. The European mesothelioma epidemic , 1999, British Journal of Cancer.
[22] Ramon Silva Martins,et al. Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[23] J. Herndon,et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.
[24] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[25] D. Sterman,et al. Advances in the treatment of malignant pleural mesothelioma. , 1999, Chest.
[26] R. Ginsberg,et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Gouvernet,et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging , 1993, Cancer.
[28] A. Ardizzoni,et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. , 1993, Anticancer research.
[29] M. Tucker,et al. Survival patterns for malignant mesothelioma: The seer experience , 1988, International journal of cancer.
[30] R. Shemin,et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.